These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 15073106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
    Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE.
    Cancer Res; 2004 Jun 01; 64(11):3987-93. PubMed ID: 15173012
    [Abstract] [Full Text] [Related]

  • 5. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
    Oncogene; 2004 Feb 26; 23(8):1539-48. PubMed ID: 14661056
    [Abstract] [Full Text] [Related]

  • 6. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S, Bigand C, Parmentier C, Hajri A.
    Neoplasia; 2009 Jul 26; 11(7):637-50. PubMed ID: 19568409
    [Abstract] [Full Text] [Related]

  • 7. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
    Uehara M, Domoto T, Takenaka S, Bolidong D, Takeuchi O, Miyashita T, Minamoto T.
    Cancer Sci; 2020 Dec 26; 111(12):4405-4416. PubMed ID: 32986894
    [Abstract] [Full Text] [Related]

  • 8. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
    Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE.
    Clin Cancer Res; 2005 May 01; 11(9):3433-8. PubMed ID: 15867245
    [Abstract] [Full Text] [Related]

  • 9. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells.
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
    Oncogene; 2004 Jan 15; 23(2):465-73. PubMed ID: 14724575
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ.
    Oncogene; 2008 Dec 04; 27(57):7212-22. PubMed ID: 18794807
    [Abstract] [Full Text] [Related]

  • 11. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS, Washington MK, Merchant NB.
    Clin Cancer Res; 2011 Feb 01; 17(3):483-93. PubMed ID: 21266529
    [Abstract] [Full Text] [Related]

  • 12. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X.
    J Exp Clin Cancer Res; 2017 Aug 10; 36(1):107. PubMed ID: 28797284
    [Abstract] [Full Text] [Related]

  • 13. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ.
    J Exp Clin Cancer Res; 2014 Dec 12; 33(1):102. PubMed ID: 25499121
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
    Baker CH, Trevino JG, Summy JM, Zhang F, Caron A, Nesbit M, Gallick GE, Fidler IJ.
    Int J Oncol; 2006 Jul 12; 29(1):125-38. PubMed ID: 16773192
    [Abstract] [Full Text] [Related]

  • 15. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS.
    Carcinogenesis; 2014 Oct 12; 35(10):2203-13. PubMed ID: 24879635
    [Abstract] [Full Text] [Related]

  • 16. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R, Thomson JM, Govindarajan R.
    PLoS One; 2013 Oct 12; 8(1):e53436. PubMed ID: 23335963
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K, Fidler IJ.
    Clin Cancer Res; 2004 Apr 01; 10(7):2299-306. PubMed ID: 15073105
    [Abstract] [Full Text] [Related]

  • 18. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
    Liau SS, Ashley SW, Whang EE.
    J Gastrointest Surg; 2006 Nov 01; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
    [Abstract] [Full Text] [Related]

  • 19. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
    Liu Q, Song C, Li J, Liu M, Fu L, Jiang J, Zeng Z, Zhu H.
    Med Oncol; 2022 Jun 18; 39(9):124. PubMed ID: 35716217
    [Abstract] [Full Text] [Related]

  • 20. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J, Guo Y, Wu H, Xiong J, Peng T.
    Mol Med; 2021 Apr 13; 27(1):38. PubMed ID: 33849427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.